Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Egg yolk lecithin for injection, at pharmaceutical grade BP EP USP, stands out as a refined, highly purified phospholipid raw material derived from the yolk of chicken eggs. Used in fields such as parenteral nutrition, this specialty lipid plays a vital role in crafting lipid emulsions for injection, thanks to its compatibility with human physiology and purity standards set forth by global pharmacopeias. This grade satisfies stringent requirements for safe medical use, providing a reliable, consistent source of lecithin that meets European Pharmacopoeia (EP), British Pharmacopoeia (BP), and United States Pharmacopeia (USP) standards. Whether manufactured as flakes, fine powder, solid pearls, or a syrupy liquid, egg yolk lecithin brings versatility in application, with its form depending on processing method and intended solubility.
At its chemical core, egg yolk lecithin is a complex group of phospholipids dominated by phosphatidylcholine, along with phosphatidylethanolamine and phosphatidylserine in smaller amounts. The general molecular formula of this class is C42H80NO8P, though actual arrangements vary due to the mixed fatty acid content typical of natural lecithin sources. Structurally, egg yolk lecithin forms amphiphilic molecules that readily assemble into bilayers and micelles upon dispersion in water, supporting their role as natural emulsifiers in intravenous fat emulsions. These molecules feature hydrophilic phosphate headgroups and hydrophobic fatty acid tails, a configuration essential for stabilizing oil-in-water mixtures and enabling nutrient delivery intravenously.
Ranging from yellow-beige flakes and granules to glassy solid masses and viscous, nearly clear liquids, egg yolk lecithin’s appearance changes with refinement and composition. The density typically settles between 1.03–1.07 g/cm3 at room temperature, slightly less than water, explaining why emulsions float freely when agitated. In powder or flakes, lecithin feels smooth, almost waxy when pressed between fingers, while the liquid form offers an oily viscosity. Under the microscope, crystalline domains appear at lower temperatures, but above melting point, lecithin acts as a transparent, liquid emulsion base. Here, the molecular flexibility grants high dispersibility, essential in injectable medical formulations.
Classified under HS Code 29232000, egg yolk lecithin for pharmaceutical use sits in the international tariff system alongside organic surface-active agents. With proper handling, it does not register as a hazardous or acutely toxic raw material by major chemical safety standards. Pure egg yolk lecithin holds GRAS (Generally Recognized as Safe) status by FDA rules when used in food and has a long safety record in parenteral applications. Exposure risks only rise if contaminated during processing or stored improperly, underscoring the need for compliance with GMP manufacturing. Accidental ingestion or skin contact typically poses no threat, but injection demands pharmaceutical purity to avoid immunological or pyrogenic reactions. Dust generation from dry powder can cause minor respiratory irritation in rare cases, but liquid or gel forms limit this risk; basic lab PPE mitigates any occupational hazard.
In the pharma grade context, the versatility of egg yolk lecithin reveals itself through multiple processed forms. Powder and flakes dissolve efficiently in both aqueous and alcoholic solutions, speeding up the preparation of injectable lipid emulsions. Granular or pearl forms offer controlled flow rates for mechanized mixing, reducing clumping and sticking during dosing. Liquid lecithin streamlines metered dispensing within sterile production lines and dissolves rapidly in oil-phase ingredients. Crystallization only emerges with prolonged cooling or dehydration—a situation rare in typical clinical use, but important during raw material storage. The physicochemical transition among these states means manufacturers match lecithin type to batch size and final product application, balancing process efficiency against the end-use requirements.
Lecithin’s critical function in injection solutions comes down to its ability to stabilize droplets in lipid-in-water emulsions—preventing separation and delivering fats safely alongside aqueous nutrients. Industry specs expect a consistent density of 1.03–1.07 kg/L at standard temperate conditions; this range ensures accurate formulation during compounding. Solubility characteristics depend on the medium—lecithin disperses in water with vigorous agitation, forming milky emulsions, and readily dissolves in most vegetable oils. Its molecular affinity for both oil and water phases underpins its value as a natural emulsifier superior to many synthetics. Proper storage at controlled temperatures preserves this property, as heat and moisture shifts impact density, flow, and dispersibility.
Complying with BP, EP, and USP standards means confirming traceable raw materials free from antibiotics, hormones, and avian diseases, with chain of custody spanning from hen to pharmaceutical plant. Source eggs must pass rigorous veterinary inspection; yolk separation, extraction, bleaching, and purification run under validated GMP processes to prevent batch-to-batch variability. Non-GMO sourcing has become standard, reflecting rising scrutiny over allergens and consumer preference for traceable, minimally modified biological materials. Each batch receives traceable lot numbers, and all documentation follows pharmacopoeial monographs spelling out physicochemical and microbiological limits.
Egg yolk lecithin—as with any ingredient crossing directly into the bloodstream—warrants controlled environments for compounding, sterile filtration, and packaging. The pharma grade specification, referencing EP, BP, and USP monographs, includes sampling for heavy metals, residual solvents, microbial contamination, and allergenicity. End-use performance, such as droplet size and emulsion stability, gets tracked per batch. Human exposure by injection passes decades of clinical evidence, but only with pharmaceutical purity. Any deviation from controlled supply or dilution in quality creates real clinical risks, highlighting why trusted suppliers and robust verification systems matter.
A main challenge today stems from the biological origin of this raw material. Egg production faces threats from avian diseases, antibiotic residues, and the variability of natural sources. Rigid screening and traceability protocols help, but disruptions occur with agricultural trends, climate swings, and changes in animal feed. Synthetic lecithin analogs or soy-derived products can step in, but many clinicians and manufacturers continue to trust the profile of egg yolk-derived lecithin, especially for neonatal and sensitive patient groups. Addressing these issues calls for increased transparency in supply chain documentation, investment in disease-resistant flocks, and tighter collaboration between pharmaceutical processors and raw egg specialists. In my own work with formulation chemists, collaboration between industry partners has helped us catch potential allergen risks before they reach packaging and allowed smoother adaptation to global regulatory changes. Pharmaceutical science continues pressing for scalable, safe, and sustainable lecithin, knowing patient outcomes depend on details that often start at the farm, not in the lab.
Chengguan District, Lanzhou, Gansu, China
